Celgene Corp (CELG)

112.19
NASDAQ : Health Care
Prev Close 111.26
Day Low/High 110.50 / 112.43
52 Wk Low/High 92.98 / 133.59
Avg Volume 4.34M
Exchange NASDAQ
Shares Outstanding 774.60M
Market Cap 86.18B
EPS 2.00
P/E Ratio 46.75
Div & Yield N.A. (N.A)

Latest News

Celgene Beats Estimates, Raises Earnings Outlook

Celgene Beats Estimates, Raises Earnings Outlook

Celgene shares jumped as the biotech company posted top-and bottom-line beats and raised its earnings forecast for the year.

Jim Cramer Says Oncology Drug Franchises Helping Both Celgene and Bristol-Myers

Jim Cramer Says Oncology Drug Franchises Helping Both Celgene and Bristol-Myers

Earnings reports from Celgene and Bristol-Myers show the importance of great science for pharma and biotech companies, according to Jim Cramer.

Pre-Market Activity Shows Gains For Celgene (CELG)

Pre-Market Activity Shows Gains For Celgene (CELG)

Trade-Ideas LLC identified Celgene (CELG) as a pre-market leader candidate

Celgene (CELG) Stock Climbs on Q2 Earnings, Revenue Beat

Celgene (CELG) Stock Climbs on Q2 Earnings, Revenue Beat

Celgene (CELG) stock is trading higher pre-market after reporting its 2016 second quarter financial results.

Celgene Reports Second Quarter 2016 Operating And Financial Results

Celgene Reports Second Quarter 2016 Operating And Financial Results

Celgene Corporation (NASDAQ:CELG) reported net product sales of $2,745 million for the second quarter of 2016, a 22 percent increase from the same period in 2015.

3 Stocks Dragging The Health Care Sector Downward

3 Stocks Dragging The Health Care Sector Downward

TheStreet highlights 3 stocks pushing the health care sector lower today.

Why Gilead Can't Easily Copy Celgene's 'Partner Partner Partner' Deal-Making Playbook

Why Gilead Can't Easily Copy Celgene's 'Partner Partner Partner' Deal-Making Playbook

When your top line declines, it's harder to convince investors it's okay to wait years see if a partnership in an early-stage biotech company delivers a home-run drug.

Morning Movers: BUD, VZ, CELG, GS

Morning Movers: BUD, VZ, CELG, GS

Anheuser-Busch increases its offer for SABMiller after Brexit while the Federal Reserve prepares for action against Goldman Sachs.

Celgene Can't Expand Revlimid Approval Into Non-Hodgkin Lymphoma Just Yet

Celgene Can't Expand Revlimid Approval Into Non-Hodgkin Lymphoma Just Yet

Celgene will not seek approval for Revlimid as a maintenance therapy for patients with diffuse large B-cell lymphoma based on the lack of a survival benefit in a clinical trial.

Celgene And LYSARC Provide Update On The Phase III 'REMARC' Study Of REVLIMID® Maintenance Treatment In Patients With Diffuse Large B-Cell Lymphoma Responding To First-Line R-CHOP Therapy

Celgene And LYSARC Provide Update On The Phase III 'REMARC' Study Of REVLIMID® Maintenance Treatment In Patients With Diffuse Large B-Cell Lymphoma Responding To First-Line R-CHOP Therapy

Celgene Corporation (NASDAQ: CELG) and the Lymphoma Study Association (LYSA) today announced that the Lymphoma Academic Research Organisation (LYSARC) reported initial data from a phase III, randomized, double-blind,...

Bullish and Bearish Reversals for the Week

Bullish and Bearish Reversals for the Week

Chipotle, Wendy's on the bull side and gold stocks on the bear side.

Jim Cramer's 'Mad Money' Recap: Here's What I'm Watching Next Week

Jim Cramer's 'Mad Money' Recap: Here's What I'm Watching Next Week

Cramer is gearing up for the heaviest week of this earnings season, but he's also providing his game plan for helping you be a better investor.

Celgene (CELG) Stock Is the ‘Chart of the Day’

Celgene (CELG) Stock Is the ‘Chart of the Day’

TheStreet’s Chris Versace and Bob Lang said biotech companies like Celgene (CELG) are slowly but surely staging a quiet resurgence.

Chart of the Day: Celgene

Celgene is showing relative strength on a weak market day.

ECB Decision a Dud

It denies higher prices to late-to-the-party bulls who need another lift to turn red into green.

Celgene, Jounce Therapeutics in Early Cancer Immunotherapy Development Pact

Celgene, Jounce Therapeutics in Early Cancer Immunotherapy Development Pact

Celgene continues to sprinkle cash around the biotech sector, tying up with smaller companies for first-dibs access to potentially valuable drugs and technologies.

Celgene (CELG) Is Strong On High Volume Today

Celgene (CELG) Is Strong On High Volume Today

Trade-Ideas LLC identified Celgene (CELG) as a strong on high relative volume candidate

5 Toxic Stocks to Sell as Anxiety Creeps Higher

5 Toxic Stocks to Sell as Anxiety Creeps Higher

It's time to unload these toxic stocks from your portfolio.

Could the Dow Jump Up Another 400 Points by Year-End?

Could the Dow Jump Up Another 400 Points by Year-End?

Concerns that the market is overvalued continue to arise as the S&P 500 has increased by 7.6% during the past two weeks. But there may still be room for growth.

Next Up for Celgene's Crohn's Pill: A Snapshot Inside Patients' Colons

Next Up for Celgene's Crohn's Pill: A Snapshot Inside Patients' Colons

GED-0301 is one of three drugs -- Otezla and ozanimod are the others -- which form the core of Celgene's burgeoning immunology and inflammation franchise.

Biotechs and Builders Will Rock 2Q Earnings

Biotechs and Builders Will Rock 2Q Earnings

A look at who will be up and who will down this earnings season.

Cramer: 10 Stocks That Need to Start Doing Better

Cramer: 10 Stocks That Need to Start Doing Better

They need to do something that makes them stand out as stocks you want to own, not avoid.

CELG, REGN, DPZ: Jim Cramer's Views

CELG, REGN, DPZ: Jim Cramer's Views

Cramer shares his views on why something could be up in biotech, restaurants and retail. Celgene, Regeneron and Domino's are among the stocks discussed.

Celgene Shares Likely to Jump on Potential $2B 'Orphan' Drug: RBC

Celgene Shares Likely to Jump on Potential $2B 'Orphan' Drug: RBC

Shareholders could be in for a surprise if an upcoming drug for pediatric Crohn's gains FDA approval.

5 Stocks I Like for 2016's Second Half

From Celgene to Ford, these names look promising.

Medivation Tries to Prove Its Worth

Medivation Tries to Prove Its Worth

A call with investors Wednesday highlights drugs in the pipeline that could be attractive to bidders that reportedly include Sanofi, Pfizer and Celgene, among others.

Wall Street Closes Higher as Fed Doves Make Case for Waiting on Rates

Wall Street Closes Higher as Fed Doves Make Case for Waiting on Rates

A dovish Federal Reserve in June pushes equities, crude to close around session highs.